…
Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company operates in three segments: Occupational Health centers, Onsite health clinics, and Other business. It offers occupational health services, including workers compensation, employer, and consumer health services; and employer-sponsored primary care services at workplace, including mobile health and episodic specialty testing services. It also operates Concentra Telemed, a telemedicine platform for the treatment of work-related injuries and illnesses; Concentra Pharmacy for distributing repackaged medications; and Concentra Medical Compliance Administration, a third-party administrator that helps to manage abuse testing programs for employers with regulated or non-regulated workforces. In addition, the company provides injury care, primary care, urgent care, preventive care, clinical testing, physical examinations and evaluations, drug and alcohol screenings, clinical testing, vaccinations and other preventive care, and a range of consultative services designed to protect employees from workplace hazards. The company was founded in 1979 and is based in Addison, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public disclosures for Concentra Group Holdings Parent, Inc. (NYSE: CON) are limited, so its core business and long-term growth drivers are not clearly documented in available filings. Any upside depends on the performance of underlying subsidiaries or future strategic transactions the company may pursue, which could support scalable cash generation if executed and disclosed.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 223.78M | 231.39M | 242.63M | 224.90M | 275.56M |
| Minority interest | -6.43M | -5.35M | -4.80M | -5.52M | -7.16M |
| Net income | 172.80M | 166.54M | 179.95M | 166.73M | 208.88M |
| Selling general administrative | 203.31M | 156.32M | 152.00M | 0.15M | 0.16M |
| Selling and marketing expenses | - | - | 151.85M | 149.83M | 157.55M |
| Gross profit | 613.09M | 527.98M | 512.43M | 408.19M | 427.98M |
| Reconciled depreciation | 75.82M | 67.18M | 73.05M | 73.67M | 82.21M |
| Ebit | 333.07M | 301.09M | 287.10M | 256.54M | 307.42M |
| Ebitda | 408.88M | 368.26M | 360.15M | 330.20M | 389.63M |
| Depreciation and amortization | 75.82M | 67.18M | 73.05M | 73.67M | 82.21M |
| Operating income | 2087.58M | 304.76M | 287.63M | 258.22M | 270.26M |
| Other operating expenses | 75.82M | 1595.43M | 1550.45M | 1466.14M | 1461.78M |
| Interest expense | 109.29M | 69.69M | 114.04M | 31.64M | 31.86M |
| Tax provision | 50.98M | 59.50M | 40.26M | 52.65M | 59.53M |
| Interest income | 109.29M | 73.37M | 45.00M | 33.22M | - |
| Net interest income | -109.29M | -69.69M | -114.04M | -31.64M | -31.86M |
| Income tax expense | 50.98M | 59.50M | 57.89M | 52.65M | 59.53M |
| Total revenue | 2163.40M | 1900.19M | 1838.08M | 1724.36M | 1732.04M |
| Total operating expenses | -1474.51M | 223.21M | 224.80M | 149.98M | 157.71M |
| Cost of revenue | 1550.32M | 1372.22M | 1325.65M | 1316.17M | 1304.06M |
| Total other income expense net | -1863.81M | -73.37M | -45.00M | -33.32M | 5.30M |
| Net income from continuing ops | 172.85M | 171.90M | 132.43M | 172.24M | 216.04M |
| Net income applicable to common shares | 328.34M | 333.09M | 359.89M | 333.45M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 3038.16M | 2521.16M | 2487.77M | 2297.24M | - |
| Intangible assets | 242.56M | 204.72M | 224.77M | 247.57M | - |
| Other current assets | 45.30M | 36.23M | 46.85M | 40.71M | - |
| Total liab | 2617.73M | 2222.44M | 1310.33M | 1301.12M | - |
| Total stockholder equity | 393.28M | 275.67M | 1155.60M | 973.32M | - |
| Other current liab | 218.54M | 200.35M | 179.42M | 178.88M | - |
| Common stock | 1.29M | 1.28M | 470.30M | 464.73M | - |
| Capital stock | 1.29M | 1.28M | - | - | - |
| Retained earnings | 146.45M | 13.55M | 685.29M | 508.59M | - |
| Good will | 1479.19M | 1234.71M | 1229.74M | 1225.87M | - |
| Other assets | 44.58M | 11.00M | -154.21M | 5.24M | - |
| Cash | 79.90M | 183.25M | 31.37M | 37.66M | - |
| Total current liabilities | 337.25M | 307.19M | 274.63M | 279.63M | - |
| Current deferred revenue | - | - | 0.40M | 0.05M | - |
| Net debt | 2022.72M | 1768.11M | 873.63M | 1001.99M | - |
| Short term debt | 95.32M | 85.53M | 74.40M | 72.97M | - |
| Short long term debt | 10.74M | 10.09M | 0.00M | 1.67M | - |
| Short long term debt total | 2102.62M | 1951.37M | 905.00M | 1039.65M | - |
| Other stockholder equity | 248.90M | 260.84M | - | - | - |
| Property plant equipment | 708.96M | 633.52M | 576.22M | 533.93M | - |
| Total current assets | 383.10M | 437.21M | 294.42M | 284.63M | - |
| Net receivables | 257.90M | 217.72M | 216.19M | 206.26M | - |
| Long term debt | 1563.66M | 1468.92M | 0.47M | 633.91M | - |
| Accounts payable | 21.00M | 19.75M | 20.41M | 27.67M | - |
| Accumulated other comprehensive income | -3.35M | - | - | - | - |
| Non currrent assets other | 200.23M | 11.00M | 8.41M | 5.24M | - |
| Non current assets total | 2655.06M | 2083.96M | 2193.35M | 2012.61M | - |
| Capital lease obligations | 528.22M | 472.36M | 0.43M | 404.07M | - |
| Long term debt total | 1563.66M | 1468.92M | 473.29M | 633.91M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -71.27M | -75.31M | -57.75M | -61.80M |
| Total cashflows from investing activities | -414.86M | -71.27M | -75.31M | -57.75M | -61.80M |
| Net borrowings | 90.39M | 999.95M | -161.69M | -184.68M | -326.89M |
| Total cash from financing activities | 32.10M | -51.53M | -165.29M | -209.86M | -342.59M |
| Net income | 172.80M | 171.90M | 184.74M | 172.24M | 216.04M |
| Change in cash | -103.36M | 151.88M | -6.28M | 6.73M | -113.75M |
| Begin period cash flow | 183.25M | 31.37M | 37.66M | 30.93M | 144.68M |
| End period cash flow | 79.90M | 183.25M | 31.37M | 37.66M | 30.93M |
| Total cash from operating activities | 279.40M | 274.68M | 234.32M | 274.34M | 290.64M |
| Issuance of capital stock | 0.00M | 511.20M | 0.00M | 0.00M | - |
| Depreciation | 75.82M | 67.18M | 73.05M | 73.67M | 82.21M |
| Other cashflows from investing activities | -414.86M | 0.03M | 0.04M | 0.04M | 5.09M |
| Dividends paid | 32.08M | 1543.64M | 6.13M | 6.29M | 6.71M |
| Change to account receivables | -11.14M | -1.60M | -10.26M | -5.93M | 12.52M |
| Sale purchase of stock | -22.42M | -15.40M | -5.32M | -29.05M | -23.40M |
| Other cashflows from financing activities | -3.78M | -3.63M | 4.51M | 3.87M | -15.70M |
| Capital expenditures | 82.33M | 64.33M | 69.34M | 45.98M | 46.79M |
| Change in working capital | 7.96M | 30.18M | -18.70M | 33.92M | -7.28M |
| Stock based compensation | 10.49M | 2.33M | 0.65M | 2.14M | 2.14M |
| Other non cash items | 98.64M | 5.50M | 0.86M | 1.01M | -1.14M |
| Free cash flow | 197.06M | 210.35M | 164.98M | 228.35M | 243.85M |
Sector: Healthcare Industry: Medical Care Facilities
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CON Concentra Group Holdings Parent, Inc. |
-1.00 2.30% |
42.56 | 17.60 | 15.97 | 1.36 | 7.47 | 2.29 | 12.13 |
| HCA HCA Healthcare, Inc. |
-7.21 1.41% |
503.49 | 14.27 | 13.46 | 1.21 | 291.34 | 1.83 | 8.99 |
| THC Tenet Healthcare Corporation |
-9.29 3.18% |
282.96 | 10.08 | 12.66 | 0.96 | 4.57 | 1.43 | 5.80 |
| FSNUY Fresenius SE & Co KGaA ADR |
0.09 0.62% |
14.50 | 16.87 | 9.44 | 0.42 | 0.78 | 0.79 | 5.37 |
| JDHIY JD Health International Inc |
- -% |
4.81 | 62.50 | 35.97 | 0.30 | 2.32 | 0.16 | 3.90 |
Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company operates in three segments: Occupational Health centers, Onsite health clinics, and Other business. It offers occupational health services, including workers compensation, employer, and consumer health services; and employer-sponsored primary care services at workplace, including mobile health and episodic specialty testing services. It also operates Concentra Telemed, a telemedicine platform for the treatment of work-related injuries and illnesses; Concentra Pharmacy for distributing repackaged medications; and Concentra Medical Compliance Administration, a third-party administrator that helps to manage abuse testing programs for employers with regulated or non-regulated workforces. In addition, the company provides injury care, primary care, urgent care, preventive care, clinical testing, physical examinations and evaluations, drug and alcohol screenings, clinical testing, vaccinations and other preventive care, and a range of consultative services designed to protect employees from workplace hazards. The company was founded in 1979 and is based in Addison, Texas.
| Name | Title | Year Born |
|---|---|---|
| Mr. William Keith Newton | CEO & Director | 1963 |
| Mr. Matthew T. DiCanio M.B.A. | President & CFO | 1983 |
| Mr. John A. deLorimier | Executive VP and Chief Information & Technology Officer | 1960 |
| Mr. Timothy F. Ryan | Executive VP & Chief Legal Counsel | 1961 |
| Dr. John R. Anderson DO, FACOEM | Executive VP & Chief Medical Officer | 1950 |
| Ms. Su Zan Nelson CPA | Executive VP & Chief Accounting Officer | 1964 |
| Mr. Thomas A. Devasia | Executive VP and Chief Marketing & Innovation Officer | 1970 |
| Ms. Danielle Kendall | Executive VP & Chief People Officer | 1969 |
| Mr. Giovanni Gallara | Executive VP & Chief Clinical Services Officer | 1975 |
| Mr. Michael A. Kosuth | Executive VP & COO of East | 1958 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.